Takeda’s Underlying Revenue Skids 0.2% in 1st Half as Rare Disease Biz Weighs

Takeda CEO Christophe Weber Takeda Pharmaceutical’s group sales jumped nearly 90% in the first half of FY2019 thanks to its Shire buyout in January, but it treaded water on an underlying revenue basis as its acquired hemophilia franchise was hit...read more